title: Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study.
abstract: OBJECTIVE
  We analysed the effects of 6-months' treatment with octreotide s.c. and lanreotide-SR on circulating GH and IGF-I levels in acromegaly.
  
  
  METHODS
  Open retrospective study.
  
  
  METHODS
  Thirty-eight patients with active acromegaly (plasma IGF-I levels greater than 2 standard deviations for age-matched controls and increased serum GH levels not suppressible by oral glucose load) were studied. All patients received s.c. octreotide at a dose of 150-600 microg/day for six months as first therapy and subsequently, lanreotide i.m., 30-60 mg either at 14 or 10 day intervals, for 6 months. A 3 months' washout was applied before starting lanreotide treatment.
  
  
  METHODS
  Mean serum GH levels (from three samples), IGF-I, and clinical examination were performed before and 30, 60, 90 and 180 days after octreotide and lanreotide treatments. Safety tests, HbA1c and, thyroid function were evaluated every three months.
  
  
  RESULTS
  Circulating GH and IGF-I levels were significantly reduced (P < 0.001) after one, three and six months of both octreotide and lanreotide treatment. The absolute values were lower and the percent decrease in serum GH levels obtained after octreotide treatment was significantly greater, at all scheduled assessments, than after lanreotide (P < 0.01). Serum IGF-I levels during octreotide were significantly lower only after the first month of therapy (P < 0.01).
  
  
  CONCLUSIONS
  Our study shows that octreotide s.c. is able to induce an earlier reduction in IGF-I levels and a more marked reduction in GH levels than lanreotide. However, after six months of therapy the number of patients with safe GH levels and normal IGF-I age-matched levels, was similar with both drugs. Therefore we suggest that octreotide treatment be preferentially used in the short-term presurgical treatment, while lanreotide can be used in chronic therapy when better compliance is necessary.
authors.affiliation: Division of Endocrinology, Department of Internal Medicine, University of Turin, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Razzore
authors.forename: A
authors.initials: A
authors.lastname: Colao
authors.forename: R
authors.initials: R
authors.lastname: Baldelli
authors.forename: D
authors.initials: D
authors.lastname: Gaia
authors.forename: P
authors.initials: P
authors.lastname: Marzullo
authors.forename: E
authors.initials: E
authors.lastname: Ferretti
authors.forename: D
authors.initials: D
authors.lastname: Ferone
authors.forename: M L
authors.initials: ML
authors.lastname: Jaffrain-Rea
authors.forename: G
authors.initials: G
authors.lastname: Tamburrano
authors.forename: G
authors.initials: G
authors.lastname: Lombardi
authors.forename: F
authors.initials: F
authors.lastname: Camanni
authors.forename: E
authors.initials: E
authors.lastname: Ciccarelli
mesh_terms: D000172:Acromegaly / Q000097:blood / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D004334:Drug Administration Schedule; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D012189:Retrospective Studies; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018709:Statistics, Nonparametric
chemical_list: D018931:Antineoplastic Agents, Hormonal; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide